UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

Rena Callahan, MD

Print
Email

Rena Desai Callahan, MD

UCLA Physician Rena Desai  Callahan, MD specializes in Hematology & Oncology.
Specialty
Hematology & Oncology
Gender
Female
Language Spoken
English
Hospital Affiliation
Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica
State License Number
A94238
Contact
(661) 255-5350 Santa Clarita
(310) 829-5471 Santa Monica
(310) 794-4955 Westwood
PRACTICE LOCATION

Santa Clarita
23929 McBean Parkway, Suite 215
Valencia, CA 91355

Santa Monica
2020 Santa Monica Blvd, Suite 230
Santa Monica, CA 90404

Westwood
100 Medical Plaza, Suite 550
Los Angeles, CA 90095

MEDICAL BOARD CERTIFICATION
Medical Oncology, American Board of Internal Medicine, 2011
Hematology, American Board of Internal Medicine, 2011
Internal Medicine, American Board of Internal Medicine, 2007
EDUCATION
Fellowship
Hematology & Medical Oncology, UCLA School of Medicine, 2008 - 2011
Residency
Internal Medicine, UCLA School of Medicine, 2005 - 2007
Internship
Internal Medicine, UCLA School of Medicine, 2004 - 2005
Medical Degree
MD, University of Pennsylvania School of Medicine, 2004
CLINICAL INTEREST
Advanced Malignancies, Antiphospholipid, Biliary, Breast, Cancers of the Digestive Tract, Chronic Myelogenous Leukemia, Esophageal Cancer, Gastric Cancer, Gastrointestinal Malignancies, General Hematology, General Oncology, Genitourinary, Geriatric Breast Cancer, Geriatric Lung Cancer, Gynecologic Oncology, Head and Neck Cancers, Hepatobiliary Cancers, Laryngeal Cancer, Liver Cancer, Lung Cancer, Lung Cancer & Chest Malignancies, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Cancer, Pancreas, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sickle Cell Anemia, Testicular Cancer, Thoracic Cancer, Unknown Primary, Waldenstrom's Disease
AFFILIATION
Department Affiliation
Physician, Hematology / Oncology, Breast Cancer Program
MORE INFORMATION
Research Interest
breast cancer, treating side effects of cancer therapy
Additional Information
Dr. Callahan attended Yale University and obtained a BS in Biology. She later attended the University of Pennsylvania School of Medicine where she graduated with high honors, Alpha Omega Alpha. She completed her Internal Medicine and Hematology/Oncology training at UCLA. Dr. Callahan is dedicated to providing patient centered care. She has a unique interest in how complementary therapies, such as meditation, yoga, reiki, and nutritional supplements can be integrated with Western evidence based medicine.

Specialty

  • Breast Cancer
  • Gynecologic malignancies
  • General Hematology-Oncology
Awards & Recognition
  • Commendation for Excellence in Medical Student Teaching, UCLA, 2007
  • Commendation for Excellence in Medical Student Teaching, UCLA, 2006
  • Commendation for Excellence in Medical Student Teaching, UCLA, 2005
  • Russell J. Stumacher Memorial Award, for academic and artistic excellence, University of Pennsylvania School of Medicine, 2004
  • Glasgow Rubin Award, for academic excellence, University of Pennsylvania School of Medicine, 2004
  • Alpha Omega Alpha medical honor society, inducted 2003 
  • Yale Class of 1956, Summer Fellowship for Study Abroad, 1996
Publications
  1. RD Callahan, SA Hurvitz. HER2-Positive Breast Cancer: Current Management of Early, Advanced, and Recurrent Disease. Current Opinions in Obstetrics and Gynecology, 2011 Feb. 23 (1):37-43.
  2. R.Callahan, R. Patel, D.Chan, M.Allison, B. Dicarlo, L. Bosserman, A. Kennedy, L.M. Zehngebot, J. Miller, A.E. Giuliano, B. Spivack, L.S. Lin, D.J. Slamon, S.A. Hurvitz. Phase II Trial of Presurgical Treatment with Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H+Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin (C) with Trastuzumab (TCH) or Lapatinib (TCTy) or the combination of Trastuzumab and Lapatinib (TCHTy) in Patients with HER2+ Breast Cancer. 2010 San Antonio Breast Cancer Symposium, December 2010.
  3. Richard P. Tonino, Pierre J. Meunier, Ronald Emkey, Jose A. Rodriguez-Portales, Charles-Joel Menkes, Richard D. Wasnich, Henry G. Bone, Arthur C. Santora, Mei Wu, Rena Desai, and Philip D. Ross. “Skeletal benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women.” J. Clin. Endocrinol. Metab. 2000. 85: 3109-3115.
  4. Rena Desai Callahan, K. Rajender Reddy. “Liver Disease in Pregnancy.” The Clinician’s Guide to Liver Disease. Ed. Reddy KR and Faust T. Philadelphia: Slack, 2006: 211-230.
  5. Richard P. Tonino, Pierre J. Meunier, Ronald Emkey, Jose A. Rodriguez-Portales, Charles-Joel Menkes, Richard D. Wasnich, Henry G. Bone, Arthur C. Santora, Mei Wu, Rena Desai, and Philip D. Ross. “Efficacy and Tolerability of Alendronate (7 years), and Effect of Discontinuation.” The 8th Annual Congress on Women’s Health and Gender Based Medicine, Hilton Head, SC, June 2000.
  6. Rena Desai, Kirti Shetty, Kim M. Olthoff, Abraham Shaked, Colleen M. Brensinger, K. Rajender Reddy. The Tokyo Score in the Prognosis of Hepatocellular Carcinoma. Young Investigator’s Forum, Controversies in Transplantation. March 2004.
  7. Christopher Gasink, Stephen Rulyak, Stephen Rubesin, Rena Desai, James Lewis, Bernard Birnbaum, Jill E. Jacobs, Matthew Gardiner, Gary R. Lichtenstein. Ileal Thickening: Radiographic Features Predictive of Crohn's Disease on Abdominal CT Scan. Digestive Disease Week, May 2004.
  8. Rena Callahan, Ashkan Lashkari, Baldeep Singh. Myositis Ossificans. Society for General Internal Medicine Annual Meeting, March 2006.
Back to top
Referring a Patient to UCLA
Our staff will assist you in selecting the appropriate UCLA clinical department for your patient.

Find out how to refer a patient
Dr. Rena Desai Callahan,  click here to update your profile.